Rx Product News (May 2017)

XERMELO

MARKETED BY: Lexicon Pharmaceuticals

INDICATION: The FDA has approved Xermelo (telotristat ethyl) 250 mg as the first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

DOSAGE FORM: Tablets: 250 mg

FOR MORE INFORMATION: xermelo.com

QTERN

MARKETED BY: AstraZeneca

INDICATION: AstraZeneca has announced the FDA approval of once-daily Qtern (10 mg dapagliflozin and 5 mg saxagliptin) for the treatment of type 2 diabetes. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes who have inadequate control with dapagliflozin or who are already being treated with dapagliflozin and saxagliptin.

DOSAGE FORM: Tablet: 10 mg dapagliflozin/5 mg saxagliptin

FOR MORE INFORMATION: astrazeneca.com

KISQALI

MARKETED BY: Novartis

INDICATION: The FDA has approved Kisqali (ribociclib) in combination with an aromatase inhibitor as initial endocrine-based therapy treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.

DOSAGE FORM: TABLETS: 200 mg

FOR MORE INFORMATION: Novartis.com

KEYTRUDA

MARKETED BY: Merck

INDICATION: The FDA has approved Keytruda’s indication for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma or who have relapsed after 3 or more prior lines of therapy.

DOSAGE FORM: Injection: 200 mg for adults; up to 200 mg for pediatrics

FOR MORE INFORMATION: Keytruda.com